-
公开(公告)号：US20210322490A1
公开(公告)日：2021-10-21
申请号：US17054433
申请日：2019-05-08
Applicant: Genome And Company
Inventor： Hansoo Park , Shinyoung Park , Eun Ju Lee , Jae-Sung Yeon , Hye Hee Jeon , Wonduck Kim , Joo-Yeon Chung , Areum Jeong , Youn Kyung Houh , Jinyoung Sohn , Yun Yeon Kim , Sang Gyun Kim , Suro Lee
IPC: A61K35/745 , C12N1/20 , A61K45/06 , C07K16/28
Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.
-
公开(公告)号：US11787870B2
公开(公告)日：2023-10-17
申请号：US17041220
申请日：2019-05-15
Applicant: GENOME AND COMPANY
Inventor： Kyoung Wan Yoon , Youn Kyung Houh , Bu-Nam Jeon , Jinyoung Sohn , Yun Yeon Kim , Suro Lee , Joo-Yeon Chung , Areum Jeong
IPC: C07K16/28 , A61P35/00 , C12N15/113
CPC classification number: C07K16/2896 , A61P35/00 , C12N15/1138 , C07K2317/55
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an LRIT2 inhibitor as an active ingredient. The LRIT2 inhibitor according to the present invention can increase the activity of immune cells, and thus can be used as an immune enhancer. Also, the LRIT2 inhibitor according to the present invention can effectively prevent or treat cancer by enhancing the immunity of an individual.
-
公开(公告)号：US20210138003A1
公开(公告)日：2021-05-13
申请号：US17096031
申请日：2020-11-12
Applicant: Genome And Company
Inventor： Hansoo Park , Shinyoung Park , Eun Ju Lee , Jae-Sung Yeon , Hye Hee Jeon , Wonduck Kim , Joo-Yeon Chung , Areum Jeong , Youn Kyung Houh , Jinyoung Sohn , Yun Yeon Kim , Sang Gyun Kim , Suro Lee
IPC: A61K35/745 , A61K31/282 , A61K31/519 , A61K33/243 , A61K31/7068 , A61K31/513 , A61K31/675 , A61K31/337 , A61K31/475 , A61K31/704 , A61K31/7048 , A61K39/395 , A61P35/00 , A61K35/744
Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.
-
公开(公告)号：US12214004B2
公开(公告)日：2025-02-04
申请号：US17096031
申请日：2020-11-12
Applicant: Genome And Company
Inventor： Hansoo Park , Shinyoung Park , Eun Ju Lee , Jae-Sung Yeon , Hye Hee Jeon , Wonduck Kim , Joo-Yeon Chung , Areum Jeong , Youn Kyung Houh , Jinyoung Sohn , Yun Yeon Kim , Sang Gyun Kim , Suro Lee
IPC: A61K35/745 , A61K31/282 , A61K31/337 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/243 , A61K35/744 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/28 , C12N1/20 , A61K39/00
Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.
-
公开(公告)号：US20190216840A1
公开(公告)日：2019-07-18
申请号：US16245436
申请日：2019-01-11
Applicant: Genome and Company
Inventor： Hansoo PARK , Kyoung-Wan Yoon , Jinyoung Sohn , Yun Yeon Kim , Suro Lee , Youn Kyung Houh , Joo-Yeon Chung , Areum Jeong
IPC: A61K31/7088 , A61P35/04 , C12Q1/02 , G01N33/574 , C12N15/113
CPC classification number: A61K31/7088 , A61P35/04 , C12N15/1136 , C12N2310/113 , C12Q1/025 , G01N33/574
Abstract: The present disclosure is based on the discovery that the inhibition of KIRREL2 activity or expression significantly inhibits the development, growth, invasion, and metastasis of cancer. The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising KIRREL2 inhibitor. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising KIRREL2 inhibitor. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL2, and a method of providing information necessary for analysis of cancer prognosis using KIRREL2.
